This video presents a fundamental analysis of Pfizer stock, ticker PFE. The analyst begins by noting that pharmaceutical stocks, specifically PFE, have had some positive news, due to a deal with the current US administration alleviating risks for investors. He mentions his year-long buy rating on PFE and other pharmaceuticals including Novo Nordisk and Eli Lilly. He points out the recent rise in pharmaceutical stock prices, fueled by an agreement where Pfizer will slash drug prices for Americans enrolled in Medicaid in exchange for a three-year reprieve on import tariffs. Pfizer also agreed to invest $70 billion in the US under an agreement with President Donald Trump. The analyst discusses the frequent changes in tariff policy under the current administration and the intrinsic value per share that he calculates for PFE at $75.25, noting that the current market price, is below the share's intrinsic value. The video concludes with the analyst reiterating a buy rating on Pfizer for long-term investors, acknowledging the high risks currently involved but the potential of the company.